Payers must balance patient access to biopharmaceuticals and cost containment. A public payer such as Medicare and its contractors is no different in this regard. Yet, payers may in some cases be ...
The Centers for Medicare & Medicaid Services (CMS) recently announced its decision to allow Medicare Advantage organizations (MAOs) to implement step therapy for Part B drugs and services beginning ...
A recent policy change that would allow Medicare Advantage plans to use step therapy for Medicare Part B drugs is creating yet another dividing line between insurers and providers.
The Trump administration will allow Medicare Advantage plans to negotiate prices for Part B drugs by providing them the opportunity to create plans that utilize step therapy. However, some in the ...
Last Tuesday, the Centers for Medicare and Medicaid Services (CMS) took its latest action in the area of drug pricing. CMS gave Medicare Advantage (MA) plans the ability to use step therapy, in which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results